<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003779</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 06/98</org_study_id>
    <secondary_id>SWS-SAKK-06/98</secondary_id>
    <secondary_id>EU-98075</secondary_id>
    <nct_id>NCT00003779</nct_id>
  </id_info>
  <brief_title>Biological Therapy in Treating Patients With Bladder Cancer</brief_title>
  <official_title>A Prospective Randomized Trial for the Comparison of Two BCG Strains (Bacille Calmette-Guerin) in the Prophylaxis of Papollary Bladder Tumors Stage Ta and T1 and Treatment of Carcinoma in Situ</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system&#xD;
      and stop cancer cells from growing. It is not yet known which type of BCG is more effective&#xD;
      for bladder cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of two different types of&#xD;
      BCG in treating patients who have bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare two strains of BCG (Connaught vs Tice) in terms of efficacy (yearly&#xD;
      relapse rate) and tolerability in patients with Ta or T1 papillary carcinoma of the urinary&#xD;
      bladder or carcinoma in situ of the urinary bladder. II. Assess the role of prior exposition&#xD;
      to mycobacteria (vaccination/Tbc) for BCG treatment efficacy in these patients. III. Define&#xD;
      the role of fever occurrence as a potential indicator for BCG reactivity in these patients.&#xD;
      IV. Evaluate the p53 status of the resected tumors and IL-8 secretion into the urine as&#xD;
      predictive factors of BCG reactivity in these patients. V. Evaluate disease free interval and&#xD;
      disease free survival, time to progression, and overall survival in these patients. VI.&#xD;
      Evaluate quality of life in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      center, T stage (Ta vs T1 vs CIS), and BCG immunization status (positive, i.e., greater than&#xD;
      10 mm diameter vs negative-indeterminate, i.e., less than 10 mm diameter). All patients&#xD;
      undergo complete transurethral resection (TURB) to remove bladder tumors. A Mantoux test is&#xD;
      performed. Patients with stage T1 disease undergo a second resection within 2-4 weeks after&#xD;
      initial TURB. Patients are randomized to receive either BCG Onko-Tice (arm I) or BCG&#xD;
      Connaught (arm II). Both arms receive BCG by catheter beginning 2-14 days after the last&#xD;
      TURB. Patients must hold the BCG in the bladder for 2 hours. BCG is instilled once a week for&#xD;
      6 weeks. Quality of life is assessed before randomization, daily during first and last weeks&#xD;
      of treatment, every 6 months for the first 2 years, and then annually thereafter. Patients&#xD;
      are followed every 6 months for the first 3 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A minimum of 300 patients will be accrued for this study within 6 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess role of prior exposition to mycobacteria</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Define role of fever occurrence as potential indicator for BCG reactivity</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>BCG-Connaught</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG Onko-Tice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Connaught</intervention_name>
    <description>Compare two strains of BCG</description>
    <arm_group_label>BCG-Connaught</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tice</intervention_name>
    <description>Compare two strains of BCG</description>
    <arm_group_label>BCG Onko-Tice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed completely resected T1 or Ta papillary&#xD;
        tumors of the urinary bladder TaG2 greater than 2 relapses in 2 years TaG3 unifocal or&#xD;
        multifocal Unifocal primary T1G2-3 after a histological tumor-free second resection If&#xD;
        multiple/multifocal, worst stage and grade AND/OR Histologically and cytologically&#xD;
        confirmed primary or secondary carcinoma in situ of the urinary bladder No persistent T1&#xD;
        disease in second resection No contracted bladder (bladder capacity less than 80 mL) or&#xD;
        bladder irritation within past 5 years No urothelial carcinoma of the upper urinary tract&#xD;
        or the urethra&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 to 90 Performance status: WHO 0-1 Life expectancy: Not&#xD;
        specified Hematopoietic: Not specified Hepatic: Liver function no greater than 1.5 times&#xD;
        upper limit of normal (ULN) Renal: Renal function no greater than 1.5 times ULN Other: Not&#xD;
        pregnant or nursing Fertile patients must use effective contraception No other concurrent&#xD;
        malignancies except basocellular carcinoma No congenital or acquired immunosuppression&#xD;
        (e.g., HIV, leukemia, lymphoma, transplant recipient) No uncontrollable or untreated&#xD;
        urinary tract infection No chronic recurring bacterial cystitis&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior BCG therapy Chemotherapy: At least 3&#xD;
        months since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 5&#xD;
        years since prior radiotherapy to the bladder Surgery: See Disease Characteristics Other:&#xD;
        No prior tuberculostatic therapy No concurrent local antiseptics or antibiotics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George N. Thalmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Rentsch CA, Birkhauser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, Lagranderie M, Marchal G, Orgeur M, Bouchier C, Bachmann A, Ingersoll MA, Brosch R, Albert ML, Thalmann GN. Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol. 2014 Oct;66(4):677-88. doi: 10.1016/j.eururo.2014.02.061. Epub 2014 Mar 12.</citation>
    <PMID>24674149</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>March 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2004</study_first_posted>
  <last_update_submitted>June 24, 2019</last_update_submitted>
  <last_update_submitted_qc>June 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage 0 bladder cancer</keyword>
  <keyword>stage I bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

